Paul Parren | EVP
LAVA Therapeutics

Paul Parren, EVP, LAVA Therapeutics

Prof. Paul W.H.I. Parren is dedicated to translating antibody biology and immunotherapy knowledge into innovative therapeutics and technologies. Prof. Parren obtained his PhD at the University of Amsterdam in 1992 after which he studied correlates of protection against viruses by human antibodies at The Scripps Research Institute in La Jolla, CA, USA.  From 2002-2017, he led research and preclinical development of therapeutic antibodies for the treatment of cancer, auto-immune and inflammatory diseases at Genmab, leading to five approvals to date. He is an inventor of ofatumumab (Arzerra, 2009; KESIMPTA, 2020), daratumumab (DARZALEX, 2015), teprotumumab (Tepezza, 2020) and the bispecific antibody amivantamab (RYBREVANT, 2021) and two clinically translated technologies to generate bispecific (DuoBody) and effector-function enhanced (HexaBody) antibodies. He is a tenured Professor of Molecular Immunology at the Leiden University Medical Center in Leiden. Since 2018, he is EVP and head of R&D at Lava Therapeutics where he develops novel bispecific gamma-delta T-cell engagers for cancer therapy


Festival of Biologics Day 2 @ 11:40

A bispecific gamma-delta T cell engager targeting CD1d for the treatment of hematological cancers

last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers